Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland

This study will review medical records from hospitals in Poland to describe the demographics and baseline clinical characteristics of adults with advanced non-small cell lung cancer who received first-line nivolumab plus ipilimumab with chemotherapy in routine care between 01 January 2023 and 31 December 2023. The study will also describe treatment patterns and clinical outcomes, associated with immunotherapy.

NCT Number	NCT07526961
Lead Sponsor	Bristol-Myers Squibb
Conditions	Non-Small Cell Lung Cancer
Enrollment	240 participants
Start Date	2025-12-01
Primary Completion	2026-01-20 (estimated)
Study Completion	2026-01-20 (estimated)
Updated on ClinicalTrials.gov	2026-04-14